Comparing Curaleaf (OTCMKTS:CURLF) and Delcath Systems (NASDAQ:DCTH)

Delcath Systems (NASDAQ:DCTH) and Curaleaf (OTCMKTS:CURLF) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Volatility & Risk

Delcath Systems has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Curaleaf has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Institutional & Insider Ownership

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 0.0% of Curaleaf shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Delcath Systems and Curaleaf’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
Curaleaf	-2.62%	-0.88%	-0.26%

Valuation & Earnings

This table compares Delcath Systems and Curaleaf”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23 million	6.44	$2.70 million	$0.01	1,581.00
Curaleaf	$1.27 billion	2.00	-$231.07 million	($0.13)	-83.54

Delcath Systems has higher earnings, but lower revenue than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Delcath Systems and Curaleaf, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1	0	5	1	2.86
Curaleaf	0	0	2	3	3.60

Delcath Systems presently has a consensus target price of $23.17, indicating a potential upside of 46.53%. Given Delcath Systems’ higher probable upside, analysts plainly believe Delcath Systems is more favorable than Curaleaf.

Summary

Delcath Systems beats Curaleaf on 11 of the 15 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

About Curaleaf

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.